Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations

Recently, the concept of ligand-directed signaling—the ability of different ligands of an individual receptor to promote distinct patterns of cellular response—has gained much traction in the field of drug discovery, with the potential to sculpt biological response to favor therapeutically beneficia...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS Vol. 110; no. 13; pp. 5211 - 5216
Main Authors: Wootten, Denise, Simms, John, Miller, Laurence J., Christopoulos, Arthur, Sexton, Patrick M.
Format: Journal Article
Language:English
Published: United States National Academy of Sciences 26-03-2013
National Acad Sciences
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, the concept of ligand-directed signaling—the ability of different ligands of an individual receptor to promote distinct patterns of cellular response—has gained much traction in the field of drug discovery, with the potential to sculpt biological response to favor therapeutically beneficial signaling pathways over those leading to harmful effects. However, there is limited understanding of the mechanistic basis underlying biased signaling. The glucagon-like peptide-1 receptor is a major target for treatment of type-2 diabetes and is subject to ligand-directed signaling. Here, we demonstrate the importance of polar transmembrane residues conserved within family B G protein-coupled receptors, not only for protein folding and expression, but also in controlling activation transition, ligand-biased, and pathway-biased signaling. Distinct clusters of polar residues were important for receptor activation and signal preference, globally changing the profile of receptor response to distinct peptide ligands, including endogenous ligands glucagon-like peptide-1, oxyntomodulin, and the clinically used mimetic exendin-4.
Bibliography:http://dx.doi.org/10.1073/pnas.1221585110
Edited* by Brian K. Kobilka, Stanford University School of Medicine, Stanford, CA, and approved February 15, 2013 (received for review December 10, 2012)
1D.W. and J.S. contributed equally to this work.
Author contributions: D.W., J.S., L.J.M., A.C., and P.M.S. designed research; D.W. and J.S. performed research; D.W. and J.S. analyzed data; and D.W., J.S., L.J.M., A.C., and P.M.S. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1221585110